OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) IN PATIENTS WITH MYELOFIBROSIS (MF) EXPOSED TO JAK1/2 INHIBITORS

被引：0

作者：

Shanavas, M. ^{[1
]}

Popat, U. ^{[2
]}

Michaelis, L. C. ^{[3
]}

Fauble, V. ^{[4
]}

Mclornan, D. ^{[5
]}

Klisovic, R. ^{[6
]}

Mascarenhas, J. ^{[7
]}

Tamari, R. ^{[8
]}

Arcasoy, M. ^{[9
]}

Davies, J. ^{[10
]}

Gergis, U. ^{[11
]}

Ukaegbu, O. ^{[12
]}

Kamble, R. ^{[13
,14
]}

Storring, J. ^{[15
]}

Majhail, N. S. ^{[16
]}

Romee, R. ^{[17
]}

Lew, J. ^{[7
]}

Pagliuca, A. ^{[5
]}

Vasu, S. ^{[6
]}

Ernst, B. ^{[4
]}

Atenafu, E. ^{[1
]}

Hanif, A. ^{[3
]}

Champlin, R. ^{[2
]}

Hari, P. ^{[2
]}

Gupta, V. ^{[1
]}

机构：

[1] Princess Margaret Canc Ctr, Toronto, ON, Canada

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[3] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[4] Mayo Clin Arizona, Rochester, MN USA

[5] Kings Coll London, London, England

[6] Ohio State Univ, Columbus, OH 43210 USA

[7] Mt Sinai Med Ctr, New York, NY 10029 USA

[8] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[9] Duke Univ, Sch Med, Durham, NC 27706 USA

[10] Oxford Univ Hosp NHS Trust, Churchill Hosp, Oxford, England

[11] Weill Cornell Med Coll, New York, NY USA

[12] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[13] Baylor Coll Med, Houston, TX 77030 USA

[14] Houston Methodist Hosp, Houston, TX USA

[15] McGill Univ, Ctr Hlth, Montreal, PQ, Canada

[16] Cleveland Clin Fdn, Taussig Canc Inst, Cleveland, OH 44195 USA

[17] Washington Univ, Sch Med, St Louis, MO USA

来源：

HAEMATOLOGICA | 2015年 / 100卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

S450

引用

页码：162 / 163

页数：2

共 50 条

[41] JAK Inhibitors Prior to Allogeneic Stem Cell Transplant for Patients with Myelofibrosis: A Prospective Study
Salit, Rachel B.
Stevens, Emily
Baker, Kelsey
Scott, Bart L.
Gooley, Ted Alan
Deeg, H. Joachim
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (03) : S33 - S33
[42] ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MYELOFIBROSIS: EXPERIENCE IN OUR CENTER
Orantos Cristina, Hinojosa
Cuenca Araceli, Salamanca
Seri Anjana, Kumar
Moreno Raquel, Saldana
Jose, Ramirez Sanchez Ma
HAEMATOLOGICA, 2021, 106 (10) : 272 - 273
[43] Outcome of allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia
Ditschkowski, M
Elmaagacli, AH
Trenschel, R
Thiele, J
Beelen, DW
BONE MARROW TRANSPLANTATION, 2003, 31 : S108 - S109
[44] The Impact of Splenectomy in Myelofibrosis Patients before Allogeneic Hematopoietic Stem Cell Transplantation
Robin, Marie
Zine, Maryem
Chevret, Sylvie
Meignin, Veronique
Munoz-Bongrand, Nicolas
Moatti, Hannah
Xhaard, Alienor
de Fontbrune, Flore Sicre
de latour, Regis Peffault
Sarfati, Emile
Socie, Gerard
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (06) : 958 - 964
[45] Allogeneic hematopoietic cell transplantation for nnyelofibrosis (MF) in high risk patients.
Narayana, Swapna
Chhabra, Saurabh
Narra, Ravi Kishore
Szabo, Aniko
Hamadani, Mehdi
Pasquini, Marcelo C.
Shah, Nirav
Hari, Parameswaran
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[46] Adoptive immunotherapy ± Ruxolitinib and second allogeneic hematopoietic stem cell transplantation in patients with relapsed Myelofibrosis after allogeneic hematopoietic stem cell transplantation
Bogdanov, R.
Ditschkowski, M.
Steckel, N. -K.
Klisanin, V.
Kordelas, L.
Trenschel, R.
Beelen, D. W.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 60 - 61
[47] Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis Treated With Ruxolitinib in The Pre-Transplant Period
Mensah-Glanowska, Patrycja
Szeremet, Agnieszka
Nasilowska-Adamska, Barbara
Majcherek, Maciej
Jakubas, Beata
Halaburda, Kazimierz
Wrobel, Tomasz
Czyz, Anna
BONE MARROW TRANSPLANTATION, 2021, 56 (SUPPL 1) : 146 - 147
[48] Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy
Porpaczy, Edit
Tripolt, Sabrina
Hoelbl-Kovacic, Andrea
Gisslinger, Bettina
Bago-Horvath, Zsuzsanna
Casanova-Hevia, Emilio
Clappier, Emmanuelle
Decker, Thomas
Fajmann, Sabine
Fux, Daniela A.
Greiner, Georg
Gueltekin, Sinan
Heller, Gerwin
Herkner, Harald
Hoermann, Gregor
Kiladjian, Jean-Jacques
Kolbe, Thomas
Kornauth, Christoph
Krauth, Maria-Theresa
Kralovics, Robert
Muellauer, Leonhard
Mueller, Mathias
Prchal-Murphy, Michaela
Putz, Eva Maria
Raffoux, Emmanuel
Schiefer, Ana-Iris
Schmetterer, Klaus
Schneckenleithner, Christine
Simonitsch-Klupp, Ingrid
Skrabs, Cathrin
Sperr, Wolfgang R.
Staber, Philipp Bernhard
Strobl, Birgit
Valent, Peter
Jaeger, Ulrich
Gisslinger, Heinz
Sexl, Veronika
BLOOD, 2018, 132 (07) : 694 - 706
[49] Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?
Lestang, Elsa
Peterlin, Pierre
Le Bris, Yannick
Dubruille, Viviane
Delaunay, Jacques
Godon, Catherine
Theisen, Olivier
Blin, Nicolas
Mahe, Beatrice
Gastinne, Thomas
Garnier, Alice
Touzeau, Cyrille
Voldoire, Maud
Bene, Marie C.
Le Gouill, Steven
Milpied, Noel
Mohty, Mohamad
Moreau, Philippe
Guillaume, Thierry
Chevallier, Patrice
EUROPEAN JOURNAL OF HAEMATOLOGY, 2017, 99 (01) : 60 - 69
[50] The Impact of Continuity of Care on Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation (HCT)
Khaled, Yasser
Fondaw, Megan
Balls, Jason
Smith, Tori
Solh, Melhem
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (02) : S294 - S294

← 1 2 3 4 5 →